智通财经APP获悉，荃信生物-B(02509)再涨超13%，年内累计涨幅接近300%。截至发稿，涨9.26%，报27.6港元，成交额4540.43万港元。
消息面上，荃信生物中期业绩显示，上半年收入人民币2.06亿元，同比增加359.69%；期内亏损3093.3万元，同比减少83.11%。收入大幅增长主要来源于对外授权项目首付款、里程碑付款和临床研发服务费收入及CDMO收入等。此外，荃信生物发布公告，配售500万股新股予TruMed基金，每股配售价20港元，所得款项净额约9900万港元，当中约60%用于偿还现有计息银行借款；约30%用于公司的新管线研发，包括QX027N、QX031N及QX035N；及约10%用作营运资金及其他企业用途。
智通财经APP在《从单抗到双抗，从国内到海外：荃信生物（02509）如何成为自免赛道新标杆？》中指出，凭借在自免领域十余年的深耕，荃信生物率已形成4款潜在全球首创或同类最佳的长效双抗储备，其中3款将在今年内集中递交IND。商业化方面，荃信生物在国内可以通过公司第二大股东华东医药的销售渠道销售产品，进而加快商业化步伐；在海外，公司通过BD交易把自免双抗的版图迅速铺向全球。值得注意的是，在近日的配售中，荃信生物获得真脉投资(TruMed Health Innovation Fund LP)重金入股。据悉，真脉投资曾作为基石投资者深度参与科伦博泰、映恩生物、维立志博、美丽田园等港股明星项目，被誉为香港医疗健康IPO投资的风向标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.